Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).

Cancer treatment reviews - 1 Feb 2022

Tabbò Fabrizio, Pisano Chiara, Mazieres Julien, Mezquita Laura, Nadal Ernest, Planchard David, Pradines Anne, Santamaria David, Swalduz Aurélie, Ambrogio Chiara, Novello Silvia, Ortiz-Cuaran Sandra

Abstract excerpt

The advent of high-throughput sequencing has allowed to profoundly interrogate the molecular landscape of non-small cell lung cancer (NSCLC) in the last years. These findings constitute the opportunity to better stratify these patients in order to address specific treatments to well-defined oncogene-restricted subgroups. Among them, BRAF-mutated lung cancers represent around 4% of NSCLC, thus identifying a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Identifiers

PMID: 35033867
DOI: 10.1016/j.ctrv.2021.102335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).PMID 35033867Read ↗

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read ↗

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.Semantic proximity Read ↗

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Semantic proximity Read ↗

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Advances in anti-BRAF therapies for lung cancer.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Ongoing progress in BRAF-mutated non-small cell lung cancer.Semantic proximity Read ↗

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Semantic proximity Read ↗

[Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].Semantic proximity Read ↗

Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.